F.D.A. Approves Alzheimer’s Drug Despite Fierce Debate Over Whether It Works

Aducanumab is the first new Alzheimer’s treatment in 18 years and the first to attack the disease process. But some prominent experts say there’s not enough evidence it can address cognitive symptoms.